A 5-day regimen of cyclophosphamide, adriamycin, platinum (CAP) in refractory breast cancer

Chemioterapia. 1987 Aug;6(4):310-2.

Abstract

The activity of the association of cis-platinum with Adriamycin and cyclophosphamide (CAP), as "rescue" chemotherapy for the treatment of refractory and relapsing advanced breast cancer, is presented. Of 42 evaluable patients, previously treated with chemotherapy +/- hormone therapy, 4 (9.5%) achieved a complete response, 15 (35%) had a partial response (CR + PR = 45%). Major toxicity observed was: nausea and vomiting in 95% of patients and leukopenia in 60%.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Cisplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Humans
  • Middle Aged
  • Remission Induction

Substances

  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin

Supplementary concepts

  • CISCA protocol